{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:18:54Z","timestamp":1740136734296,"version":"3.37.3"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":275,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1124\/jpet.123.001787","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T15:50:23Z","timestamp":1697817023000},"page":"19-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Neutrophil Dynamic Mass Redistribution Assay as a Medium throughput Primary Cell Screening Assay"],"prefix":"10.1016","volume":"389","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3724-2567","authenticated-orcid":false,"given":"Lisa A.","family":"Stott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armand Drieu","family":"la Rochelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine J.","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirstie A.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.001787_bib1","doi-asserted-by":"crossref","first-page":"20545","DOI":"10.1074\/jbc.271.34.20545","article-title":"The CXC chemokines growth-regulated oncogene (GRO) \u03b1, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor","volume":"271","author":"Ahuja","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.123.001787_bib2","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3389\/fimmu.2019.02257","article-title":"Therapeutic targeting of neutrophil granulocytes in inflammatory liver disease","volume":"10","author":"Bartneck","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.123.001787_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.123.001787_bib4","doi-asserted-by":"crossref","first-page":"11791","DOI":"10.1073\/pnas.0402090101","article-title":"Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury","volume":"101","author":"Bertini","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.123.001787_bib5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1476-5381.2009.00182.x","article-title":"SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor","volume":"158","author":"Bradley","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.001787_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.114.094821","article-title":"Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action","volume":"87","author":"Bradley","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.123.001787_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbcan.2019.01.005","article-title":"Potential roles and targeted therapy of the CXCLs\/CXCR2 axis in cancer and inflammatory diseases","volume":"1871","author":"Cheng","year":"2019","journal-title":"Biochimica Biophysica Acta - Rev Cancer"},{"key":"10.1124\/jpet.123.001787_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.vascn.2017.07.003","article-title":"Applying label-free dynamic mass redistribution assay for studying endogenous FPR1 receptor signalling in human neutrophils","volume":"88","author":"Christensen","year":"2017","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.123.001787_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/vaccines4030022","article-title":"The IL-8\/IL-8R axis: a double agent in tumor immune resistance","volume":"4","author":"David","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1124\/jpet.123.001787_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/10799890902976933","article-title":"Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells","volume":"29","author":"Du","year":"2009","journal-title":"J Recept Signal Transduct Res"},{"key":"10.1124\/jpet.123.001787_bib11","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.1021\/jm0609622","article-title":"Discovery of 2-hydroxy-N,N-dimethyl-3-2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylaminobenzamide (SCH 527123): a potent, orally bioavailable CXCR2\/CXCR1 receptor antagonist","volume":"49","author":"Dwyer","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.123.001787_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/imm.13200","article-title":"Understanding the mechanisms that facilitate specificity, not redundancy, of chemokine-mediated leukocyte recruitment","volume":"160","author":"Dyer","year":"2020","journal-title":"Immunology"},{"key":"10.1124\/jpet.123.001787_bib13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2174\/138620708785204144","article-title":"The use of immortalized cell lines in GPCR screening: the good, bad and ugly","volume":"11","author":"Eglen","year":"2008","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1124\/jpet.123.001787_bib14","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.ddtec.2010.05.001","article-title":"Label-free receptor assays","volume":"7","author":"Fang","year":"2011","journal-title":"Drug Discov Today Technol"},{"key":"10.1124\/jpet.123.001787_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/JLB.2A0720-432R","article-title":"Allosteric targeting of the FFA2 receptor (GPR43) restores responsiveness of desensitized human neutrophils","volume":"109","author":"Frei","year":"2021","journal-title":"J Leukoc Biol"},{"key":"10.1124\/jpet.123.001787_bib16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.intimp.2013.06.034","article-title":"Neutrophil cell surface receptors and their intracellular signal transduction pathways","volume":"17","author":"Futosi","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1124\/jpet.123.001787_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028771","article-title":"Combined boyden-flow cytometry assay improves quantification and provides phenotypification of leukocyte chemotaxis","volume":"6","author":"Gomez-Lopez","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/jpet.123.001787_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4939-2336-6_14","article-title":"Label-free biosensor assays in GPCR screening","volume":"1272","author":"Grundmann","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1124\/jpet.123.001787_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.116.237255","article-title":"Label-free dynamic mass redistribution reveals low density, pro-survival \u03b11B-adrenergic receptors in human SW480 colon carcinoma cells","volume":"361","author":"Harris","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001787_bib20","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.drudis.2017.07.015","article-title":"Label-free technology and patient cells: from early drug development to precision medicine","volume":"22","author":"Hillger","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.123.001787_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/imr.12752","article-title":"Concepts of GPCR-controlled navigation in the immune system","volume":"289","author":"L\u00e4mmermann","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1124\/jpet.123.001787_bib22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2125.2011.03968.x","article-title":"SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans","volume":"72","author":"Lazaar","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.123.001787_bib23","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.drudis.2020.06.001","article-title":"Image-based high-content screening in drug discovery","volume":"25","author":"Lin","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.123.001787_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2125.1998.00646.x","article-title":"Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration","volume":"45","author":"Liston","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.123.001787_bib25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fphar.2019.00307","article-title":"Activation of CXCL6\/CXCR1\/2 axis promotes the growth and metastasis of osteosarcoma cells in vitro and in vivo","volume":"10","author":"Liu","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.123.001787_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41586-020-2492-5","article-title":"Structural basis of CXC chemokine receptor 2 activation and signalling","volume":"585","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1124\/jpet.123.001787_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2016.08.002","article-title":"The CXCL8-CXCR1\/2 pathways in cancer","volume":"31","author":"Liu","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1124\/jpet.123.001787_bib28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/apha.12444","article-title":"Galanin modulates human and murine neutrophil activation in vitro","volume":"213","author":"Locker","year":"2015","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1124\/jpet.123.001787_bib29","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.3389\/fimmu.2018.02739","article-title":"Organ-specific mechanisms of transendothelial neutrophil migration in the lung, liver, kidney, and aorta","volume":"9","author":"Maas","year":"2018","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.123.001787_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.566953","article-title":"CXCR1 and CXCR2 inhibition by ladarixin improves neutrophil-dependent airway inflammation in mice","volume":"11","author":"Mattos","year":"2020","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.123.001787_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4137\/JCD.S11038","article-title":"Regulation of human neutrophil apoptosis and lifespan in health and disease","volume":"7","author":"McCracken","year":"2014","journal-title":"J Cell Death"},{"key":"10.1124\/jpet.123.001787_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40360-015-0017-x","article-title":"The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)\u2014 a selective CXCR2 antagonist\u2009\u2014in healthy adult subjects","volume":"16","author":"Miller","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1124\/jpet.123.001787_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pharmthera.2008.08.006","article-title":"Regulation of chemokine activity by posttranslational modification","volume":"120","author":"Mortier","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.123.001787_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bcp.12900","article-title":"Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects","volume":"82","author":"Namour","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.123.001787_bib35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41573-019-0054-z","article-title":"Neutrophils as emerging therapeutic targets","volume":"19","author":"N\u00e9meth","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.123.001787_bib36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/jpet.114.221358","article-title":"Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist","volume":"353","author":"Nicholls","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001787_bib37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1021\/bi981294s","article-title":"Amino-terminal processing of chemokine ENA-78 regulates biological activity","volume":"38","author":"Nufer","year":"1999","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.123.001787_bib38","doi-asserted-by":"crossref","first-page":"25481","DOI":"10.1074\/jbc.M301403200","article-title":"Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation","volume":"278","author":"Le Poul","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.123.001787_bib39","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1476-5381.2009.00623.x","article-title":"A common intracellular allosteric binding site for antagonists of the CXCR2 receptor","volume":"159","author":"Salchow","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.001787_bib40","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/nprot.2011.386","article-title":"Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells","volume":"6","author":"Schr\u00f6der","year":"2011","journal-title":"Nat Protoc"},{"key":"10.1124\/jpet.123.001787_bib41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.drudis.2010.06.008","article-title":"Label-free whole-cell assays: expanding the scope of GPCR screening","volume":"15","author":"Scott","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.123.001787_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.medcli.2018.08.006","article-title":"A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K\/AKT pathway","volume":"152","author":"Shang","year":"2019","journal-title":"Med Clin (Barc)"},{"key":"10.1124\/jpet.123.001787_bib43","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/s41467-021-22810-z","article-title":"Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms","volume":"12","author":"Shi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.123.001787_bib44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.it.2019.04.012","article-title":"Neutrophil diversity in health and disease","volume":"40","author":"Silvestre-Roig","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1124\/jpet.123.001787_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.10.011","article-title":"Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: a practical guide to assessing functional data","volume":"101","author":"Stott","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.123.001787_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3389\/fimmu.2018.00399","article-title":"Purinergic regulation of neutrophil function","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.123.001787_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115209","article-title":"High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathways","volume":"28","author":"Warchal","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.123.001787_bib48","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.yjmcc.2018.12.015","article-title":"High-content phenotypic assay for proliferation of human iPSC-derived cardiomyocytes identifies L-type calcium channels as targets","volume":"127","author":"Woo","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/jpet.123.001787_bib49","doi-asserted-by":"crossref","first-page":"31202","DOI":"10.1074\/jbc.271.49.31202","article-title":"Discrete steps in binding and signaling of interleukin-8 with its receptor","volume":"271","author":"Wu","year":"1996","journal-title":"J Biol Chem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.001787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:18:04Z","timestamp":1739978284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524172217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0022356524172217"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.001787","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Neutrophil Dynamic Mass Redistribution Assay as a Medium throughput Primary Cell Screening Assay","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.001787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The Author(s)","name":"copyright","label":"Copyright"}]}}